Device/Diagnostics Quarterly Deal Statistics, Q3 2013
A look at financing, M&A, and alliance activity, July–September 2013
Device and diagnostics companies both suffered declines in fundraising compared with previous quarters. The biggest medtech acquisition was Stryker’s $1.4 billion buyout of MAKO, while in diagnostics BioMeriux’s $450 million purchase of BioFire topped the list.
You may also be interested in...
While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.
In 2007, the Russian government committed $10 billion to invest in nanotechnology. About half of that has been invested, with little to show for it so far. After a recent shake-up, Rusnano is looking to prove itself and attract the private investors that could allow it eventually to privatize.
Stryker’s adoption of MAKO’s RIO (Robotic-arm Interactive Orthopedic) system could give the global medical supplier a competitive edge over other orthopedic implant makers if the company can win converts to robotic surgery by leveraging its own experience in selling capital equipment.